|Day Low/High||92.05 / 93.33|
|52 Wk Low/High||83.19 / 125.86|
SAN FRANCISCO, Sept. 21, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in AbbVie Inc.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AbbVie Inc.
- If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.
NEW YORK, Sept. 20, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of AbbVie Inc.
NEW YORK, Sept. 19, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.
The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
- Across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo
- Pooled analyses from ultIMMa-1 and ultIMMa-2 studies showed significantly more patients treated with risankizumab were symptom-free (psoriasis symptom scale [PSS] score of 0) compared to placebo and STELARA® (ustekinumab) after 16 weeks and at one year (52 weeks) compared to ustekinumab
- Minimal residual disease (MRD)-negativity is defined as having disease at a threshold of less than one chronic lymphocytic leukemia (CLL) cell per 10,000 lymphocytes in the blood or bone marrow
Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.
Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.
- Twenty-four presentations of HUMIRA® (adalimumab) and pipeline data showcase the breadth and depth of robust dermatology portfolio
NORTH CHICAGO, Ill., Aug.
- Milestone represents ninth FDA approval for IMBRUVICA in less than five years since its initial approval
- Study results (ELARIS UF-EXTEND) showed elagolix, in combination with add-back therapy, reduced heavy menstrual bleeding for up to 12 months
NEW YORK, Aug. 21, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AbbVie Inc.
Searching for dividends in this yield starved world? Check out these top 10 names.
NEW YORK, Aug. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc.
Jim Cramer takes a look at AbbVie, Greendot, Sherwin-Williams, Visteon, TransEnterix, Duke Energy, Buckeye Partners, Arch Coal and more.
Jim Cramer says that in good markets there are always multiple ways for investors to win.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
This exclusive group of stocks is among the best when it comes to returning cash to shareholders and building wealth over time.
NEW YORK, July 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.
Blue Chip stocks are the way to go right now. Here are several key names worth considering.
- Reports Second-Quarter Diluted EPS of $1.26 on a GAAP Basis; Adjusted Diluted EPS of $2.00 Reflects Growth of 40.8 Percent
This stock is still going wild after earnings.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.